Aytu BioPharma, Inc.

NasdaqCM:AYTU 株式レポート

時価総額:US$15.6m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Aytu BioPharma バランスシートの健全性

財務の健全性 基準チェック /46

Aytu BioPharmaの総株主資本は$30.8M 、総負債は$16.7Mで、負債比率は54.3%となります。総資産と総負債はそれぞれ$128.9Mと$98.1Mです。 Aytu BioPharmaの EBIT は$1.4Mで、利息カバレッジ比率289.8です。現金および短期投資は$19.8Mです。

主要情報

54.3%

負債資本比率

US$16.70m

負債

インタレスト・カバレッジ・レシオ289.8x
現金US$19.76m
エクイティUS$30.78m
負債合計US$98.09m
総資産US$128.86m

財務の健全性に関する最新情報

Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden

Jun 14
Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden

Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

Jan 23
Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

Recent updates

Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden

Jun 14
Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden

US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Feb 17
US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Feb 16
Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

Jan 23
Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too

Sep 29
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too

Aytu stock falls amid suspending clinical programs to save costs

Oct 13

Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M

Sep 27

Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder

Sep 14

Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders

Aug 16

Aytu BioPharma plunges on pricing $10M stock and warrants offering

Aug 09

Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00

May 19
Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00

Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?

Sep 11
Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?

Aytu BioPharma up 21% in afternoon trading

Jun 21

Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now

May 15
Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now

A Quick Analysis On Aytu BioScience's (NASDAQ:AYTU) CEO Compensation

Feb 14
A Quick Analysis On Aytu BioScience's (NASDAQ:AYTU) CEO Compensation

Aytu BioScience: Time To Call In The Cavalry Of Value Catalysts

Dec 31

Aytu BioScience completes safety study in critically ill COVID-19 patients

Dec 28

Aytu Bio raises 'bought deal' offering to $25M

Dec 11

Aytu BioScience: The Barcode King Is Poised For An Epic Breakout

Nov 12

財務状況分析

短期負債: AYTUの 短期資産 ( $71.1M ) は 短期負債 ( $83.7M ) をカバーしていません。

長期負債: AYTUの短期資産 ( $71.1M ) が 長期負債 ( $14.4M ) を上回っています。


デット・ツー・エクイティの歴史と分析

負債レベル: AYTU総負債よりも多くの現金を保有しています。

負債の削減: AYTUの負債対資本比率は、過去 5 年間で32%から54.3%に増加しました。


貸借対照表


キャッシュ・ランウェイ分析

過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。

安定したキャッシュランウェイ: Whilst unprofitable AYTU has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

キャッシュランウェイの予測: AYTU is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 7.3% per year.


健全な企業の発掘